Gubra - Presentation of Q2 report 2024

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 23 August at 13.00 when they present the Q2 report 2024.

Gubra consists of two business areas CRO and D&P. In the quarter Gubra raised their financial outlook for 2024, due to strong growth in Obesity within the CRO business.

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organized in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information. Gubra is listed on Nasdaq Copenhagen mid Cap, with ticker code GUBRA.

Disclaimer: HC Andersen Capital receives payment from Gubra for a Digital IR/Corporate Visibility agreement./Claus Thestrup 20 June 2024 at 11.06.